Boston Scientific rises as cardiology sales drive Q3 beat, guidance boost

[Boston Scientific Offers To Buy Guidant For $25 Billion]
Joe Raedle/Getty Images News

Boston Scientific (NYSE:BSX [https://seekingalpha.com/symbol/BSX]) traded higher on Wednesday after the MedTech giant exceeded Street forecasts with its Q3 2025 results and boosted its full-year outlook following better-than-expected sales from its cardiology unit. [https://seekingalpha.com/news/4506529-boston-scientific-non-gaap-eps-of-0_75-beats-by-0_04-revenue-of-5_07b-beats-by-100m]

Marlborough, Massachusetts-based Boston Scientific (NYSE:BSX [https://seekingalpha.com/symbol/BSX]) reported $0.75 of adjusted earnings per share on $5.1B in revenue for the quarter, implying ~19% YoY and ~20% YoY growth, exceeding the consensus by $0.04 and $100M, respectively. [https://seekingalpha.com/pr/20274850-boston-scientific-announces-results-for-third-quarter-2025#hasComeFromMpArticle=false]

As the company’s Cardiovascular net sales rose by ~22% YoY to $3.3B, sales from its Cardiology unit reached $2.64B with ~24% YoY growth on reported terms and ~19% organically, surpassing the $2.57B projected by analysts, according to Bloomberg data.

“BSX posts comfortable 3Q beat, instills confidence for FY26+,” wrote Leerink analyst Mike Kratky with an Outperform rating on the stock.

“BSX delivered another beat and raise print, which should drive a positive stock reaction and a near-term outperformance relative to peers,” added TD Cowen analyst Joshua Jennings with a Buy rating.

“This was a solid print by BSX with the Beat driven primarily by the key Cardio segment, which grew high teens,” argued Evercore ISI's Vijay Kumar, who has an Outperform rating on the stock.

Net sales from Boston Scientific’s (NYSE:BSX [https://seekingalpha.com/symbol/BSX]) Endoscopy and Urology divisions grew ~10% YoY and ~28% on a GAAP basis to reach $747M and $682M, respectively, compared to $725.6M and $664.4M in the consensus.

As for the Q4 outlook, the company estimated $0.77 - $0.79 of adjusted earnings on 14.5% YoY - 16.5% YoY of revenue growth, ahead of $0.76 and ~14% YoY growth projected by analysts, respectively.

Boston Scientific (BSX [https://seekingalpha.com/symbol/BSX]) increased its full-year outlook for revenue growth and adjusted earnings to 20% and $3.02 - $3.04 per share, respectively, compared to 18% - 19% and $2.95 - $2.99 previously and ~19% and $2.98 in the consensus. [https://seekingalpha.com/symbol/BSX/earnings/estimates?period=annual]

MORE ON BOSTON SCIENTIFIC

* Boston Scientific Corporation 2025 Q3 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4831848-boston-scientific-corporation-2025-q3-results-earnings-call-presentation]
* Boston Scientific: Not In The Most Resolute State As It Approaches Q3 Earnings [https://seekingalpha.com/article/4828727-boston-scientific-not-in-the-most-resolute-state-as-it-approaches-q3-earnings]
* 2025 Investor Day Call [https://seekingalpha.com/article/4827071-2025-investor-day-call]
* Boston Scientific Non-GAAP EPS of $0.75 beats by $0.04, revenue of $5.07B beats by $100M [https://seekingalpha.com/news/4506529-boston-scientific-non-gaap-eps-of-0_75-beats-by-0_04-revenue-of-5_07b-beats-by-100m]
* Boston Scientific Q3 2025 Earnings Preview [https://seekingalpha.com/news/4506101-boston-scientific-q3-2025-earnings-preview]